Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). (Q43412767)
Jump to navigation
Jump to search
scientific article published on 30 October 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). |
scientific article published on 30 October 2008 |
Statements
1 reference
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). (English)
1 reference
Clemens-Martin Wendtner
1 reference
Michael Hallek
1 reference
Carmen D Schweighofer
1 reference
Matthias Ritgen
1 reference
Barbara F Eichhorst
1 reference
Raymonde Busch
1 reference
Wolfgang Abenhardt
1 reference
Michael Kneba
1 reference
30 October 2008
1 reference
1 reference
Identifiers
1 reference